Oncolytic viruses as experimental treatments for malignant gliomas: Using a scourge to treat a devil
| Autor: | Daniel A. Muruve, Peter A. Forsyth, Xueqing Lun, Franz J. Zemp, Juan Carlos Corredor |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Genetic Vectors Immunology Disease Biology medicine.disease_cause General Biochemistry Genetics and Molecular Biology chemistry.chemical_compound Internal medicine medicine Humans Immunology and Allergy Virotherapy Oncolytic Virotherapy Clinical Trials as Topic Brain Neoplasms Cancer Glioma medicine.disease Immunity Innate Oncolytic virus Radiation therapy Clinical trial Oncolytic Viruses Herpes simplex virus chemistry Vaccinia Signal Transduction |
| Zdroj: | Cytokine & Growth Factor Reviews. 21:103-117 |
| ISSN: | 1359-6101 |
| Popis: | The concept of oncolytic viral therapy has a century-old history, but only within the last 20 years have oncolytic viruses been considered for the treatment of brain cancers. Viruses such as herpes, measles, and vaccinia have all been known to cause devastating cases of neurological disease in humans, yet these 'scourges' are now being harnessed in such a way that they prove very useful as cancer therapeutics. There have been 8 formal clinical trials and 3 case studies using oncolytic viruses to treat malignant glioma patients. Although some success has been reached with oncolytic therapy, overall it has fallen short of expectations. In this review we analyze the results of these trials and bring to light some of the limitations and pitfalls of this therapy, as well as present some promising preclinical work that has been proposed to circumvent such problems. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect